Cargando…
Combined aspirin and apatinib treatment suppresses gastric cancer cell proliferation
Gastric cancer (GC), one of the types of tumor most prone to malignancy, is characterized by high lethality. Numerous molecular mediators of GC have been identified, including transcription factors, signaling molecules and non-coding RNAs. Recently, inhibition of angiogenesis has emerged as a potent...
Autores principales: | Zhang, Wei, Tan, Yongsheng, Ma, Heping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666649/ https://www.ncbi.nlm.nih.gov/pubmed/29142602 http://dx.doi.org/10.3892/ol.2017.6858 |
Ejemplares similares
-
Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
por: Li, Ningning, et al.
Publicado: (2020) -
Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
por: Cui, Qingli, et al.
Publicado: (2022) -
Apatinib inhibits the proliferation of gastric cancer cells via the AKT/GSK signaling pathway in vivo
por: Chen, Yi, et al.
Publicado: (2021) -
Apatinib Suppresses Gastric Cancer Stem Cells Properties by Inhibiting the Sonic Hedgehog Pathway
por: Cao, Wanshuang, et al.
Publicado: (2021) -
Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)